Quantcast

Latest Steatohepatitis Stories

2010-01-05 05:00:00

SAN DIEGO, Jan. 5 /PRNewswire-FirstCall/ -- LifeVantage Corporation (OTC Bulletin Board: LFVN), the maker of Protandim® and TrueScience(TM) Anti-Aging Cream, science-based solutions to oxidative stress, announced today that the Company's flagship product, Protandim, a patented dietary supplement composed of five highly synergistic "indirect antioxidants", is currently the subject of two human clinical trials at the University of Colorado, Denver. The studies, entitled The...

2009-11-25 14:23:09

Findings suggest patients with nonalcoholic liver disease are candidates for transplants, but are at increased risk for metabolic syndrome complications Researchers at the University of Miami School of Medicine compared the outcomes of cirrhotic patients who underwent liver transplants for nonalcoholic steatohepatitis (NASH) versus alcoholic liver disease (ETOH) and found no statistically significant differences in post-transplant survival rates between the NASH and ETOH groups. Study...

2009-11-24 16:25:45

Impaired oxidation in liver associated with progression to NASH A recent metobolomics study by researchers from Virginia Commonwealth University Medical Center in Richmond found that impaired peroxisomal oxidation of polyunsaturated fatty acids (PUFA) is associated with the progression of nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH). The study also found significantly higher plasma monounsaturated fatty acids in the blood of patients with NAFL and NASH. Full findings...

cead820fcb520ff6d7d9f8e819492f941
2009-10-20 13:59:15

Patients with chronic hepatitis C and advanced liver disease who drink three or more cups of coffee per day have a 53% lower risk of liver disease progression than non-coffee drinkers according to a new study led by Neal Freedman, Ph.D., MPH, from the National Cancer Institute (NCI). The study found that patients with hepatitis C-related bridging fibrosis or cirrhosis who did not respond to standard disease treatment benefited from increased coffee intake. An effect on liver disease was not...

2009-10-12 05:30:00

NOVATO, Calif., Oct. 12 /PRNewswire-FirstCall/ -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq: RPTPD), announced positive findings from the completed treatment phase of its open-label Phase 2a clinical trial of delayed-release cysteamine bitartrate ("DR Cysteamine") in adolescent patients with non-alcoholic steatohepatitis ("NASH"), a progressive form of liver disease believed to affect 2% to 5% of the U.S. population. At the completion of the initial six-month...

2009-10-01 21:00:00

NEW YORK, Oct. 1 /PRNewswire/ -- Intercept Pharmaceuticals, Inc., has announced that its first-in-class farnesoid X receptor (FXR) agonist INT-747 has met the primary endpoint of improved insulin sensitization in a 6 week double blind, placebo controlled trial in type 2 diabetic patients with nonalcoholic fatty liver disease (NAFLD). By employing a euglycemic insulin clamp procedure, the study demonstrated that a single oral daily dose of INT-747 statistically significantly improved...

2009-06-01 14:58:27

The latest research in liver disease being presented at Digestive Disease Week® 2009 (DDW®) has important implications for tracking disease development in patients and for current and future transplant recipients. Researchers are making great strides in diagnosing and treating liver disease."The research being presented during DDW shows how widespread our efforts are in understanding and treating liver disease," said Brent Tetri, MD, Saint Louis University....

2009-05-29 07:58:51

Intestinal permeability and an overgrowth of bacteria in the small intestine are both associated with nonalcoholic fatty liver disease (NAFLD). These findings are revealed in a new study in the June issue of Hepatology, a journal published by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD). The article is also available online at Wiley Interscience (www.interscience.wiley.com).Previous studies have suggested that bacteria from the intestine...

2009-02-05 05:30:00

Study Evaluating Cysteamine in Collaboration with UC San Diego NOVATO, Calif., Feb. 5 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced the completion of patient enrollment in its Phase 2a open-label clinical trial to evaluate cysteamine bitartrate ("cysteamine") in patients diagnosed with non-alcoholic steatohepatitis ("NASH"). NASH, a progressive form of liver disease that accounts for approximately 10% of newly...

2008-12-08 08:21:27

Obesity is becoming one of the most common causes of liver disease in the nation. A popular surgery may resolve the dangerous disease and its cause. A recent study shows bariatric surgery, a popular and effective weight loss method for morbidly obese individuals, improves or completely resolves complications associated with nonalcoholic fatty liver disease (NAFLD) in a majority of patients. Of patients with steatosis, or fat accumulation in the liver cells, 91.6 experienced improvement or...


Word of the Day
cruet
  • A vial or small glass bottle, especially one for holding vinegar, oil, etc.; a caster for liquids.
This word is Middle English in origin, and ultimately comes from the Old French, diminutive of 'crue,' flask.
Related